Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer
Local failure of non-small-cell lung cancer (NSCLC) radiotherapy may cause continuous tumor seeding and death. Radiotherapy dose escalation has been shown to improve local control and survival. However, the toxicities associated with dose escalation are significant and limit the potential of dose escalation. Intensity modulated radiotherapy (IMRT) may have the potential to improve the therapeutic ratio for photon treatment of lung cancer by sparing surrounding normal tissues. However, lowdose exposure to normal lung and organ motion is a major concern. We have conducted several studies to address these issues and started clinical studies to evaluate the potential benefit of IMRT in patients with NSCLC. Proton radiotherapy may have greater potential to spare normal tissue and allow for further dose escalation and acceleration. We are conducting preclinical and clinical studies for imaging-guided proton radiotherapy in NSCLC. In this paper, we discuss the preliminary data, IMRT treatment guidelines, and ongoing studies for proton therapy in NSCLC.
KeywordsRadiat Oncol Biol Phys Intensity Modulate Radiation Therapy Proton Radiotherapy Tumor Motion Internal Target Volume
Unable to display preview. Download preview PDF.
- 5.Curran W, Scott C, Langer C, et al.: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 94-10 [abstract 2499]. Proc ASCO 2003, 22:621.Google Scholar
- 7.Liu HH, Wang X, Dong L, et al.: Feasibility of sparing the lung and other thoracic structures with IMRT for NSCLC. Int J Radiat Oncol Biol Phys 2004, 60:1473–1483. Dosimetric study showed that IMRT reduced the lung V20, V10, and normal tissue complication probabilties for esophagus and lung in stage I to IIIB NSCLC.PubMedCrossRefGoogle Scholar
- 8.Murshed H, Liu HH, Liao Z, et al.: Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 58:1258–1267. Dosimetric study showed that IMRT reduced the lung V20, V10, and normal tissue complication probabilties for esophagus and lung in 41 patients with locally advanced NSCLC.PubMedGoogle Scholar
- 9.Grills IS, Yan D, Martinez AA, et al.: Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensitymodulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003, 57:875–890.PubMedCrossRefGoogle Scholar
- 16.Bush DA, Slater JD, Shin BB, et al.: Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest 2004, 126:1198–1203. This study showed promising local control and survival with minimal toxicities using accelerated/escalated proton radiotherapy in stage I NSCLC.PubMedCrossRefGoogle Scholar